Last reviewed · How we verify
DOR/DTG/3TC
A fixed-dose combination of three antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication.
A fixed-dose combination of three antiretroviral agents that inhibit HIV reverse transcriptase and integrase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | DOR/DTG/3TC |
|---|---|
| Also known as | Doravirine (Pifeltro®) + Dolutegravir/Lamivudine (Dovato®) |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Drug class | Antiretroviral combination (NNRTI + INSTI + NRTI) |
| Target | HIV reverse transcriptase, HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI), dolutegravir (DTG) is an integrase strand transfer inhibitor (INSTI), and lamivudine (3TC) is a nucleoside reverse transcriptase inhibitor (NRTI). Together, they target multiple steps of HIV replication: reverse transcription of viral RNA and integration of viral DNA into the host genome, providing complementary antiviral activity.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Rash
Key clinical trials
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully (PHASE2)
- A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy (PHASE3)
- Adipose Tissue After Switch to Doravirine (NA)
- The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients (PHASE4)
- B-free Multistage Trial (PHASE4)
- Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI (PHASE4)
- DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DOR/DTG/3TC CI brief — competitive landscape report
- DOR/DTG/3TC updates RSS · CI watch RSS
- Insel Gruppe AG, University Hospital Bern portfolio CI